Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $88.17 in the prior trading day, Haemonetics Corp (NYSE: HAE) closed at $84.83, down -3.79%. In other words, the price has decreased by -$3.79 from its previous closing price. On the day, 0.77 million shares were traded. HAE stock price reached its highest trading level at $87.48 during the session, while it also had its lowest trading level at $84.76.
Ratios:
Our goal is to gain a better understanding of HAE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 112.47. For the most recent quarter (mrq), Quick Ratio is recorded 2.09 and its Current Ratio is at 3.49. In the meantime, Its Debt-to-Equity ratio is 1.39 whereas as Long-Term Debt/Eq ratio is at 1.39.
On September 13, 2024, CL King started tracking the stock assigning a Buy rating and target price of $116.
On September 11, 2024, BofA Securities started tracking the stock assigning a Neutral rating and target price of $85.BofA Securities initiated its Neutral rating on September 11, 2024, with a $85 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’24 when Lingamneni Anila bought 6,238 shares for $90.68 per share.
Strong Stewart W sold 4,312 shares of HAE for $393,039 on Jul 26 ’24. The President, Global Hospital now owns 18,196 shares after completing the transaction at $91.15 per share. On Jul 26 ’24, another insider, Strong Stewart W, who serves as the Officer of the company, bought 4,312 shares for $91.15 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HAE now has a Market Capitalization of 4260493568 and an Enterprise Value of 5443181056. As of this moment, Haemonetics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 35.23, and their Forward P/E ratio for the next fiscal year is 15.84. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.13 while its Price-to-Book (P/B) ratio in mrq is 4.86. Its current Enterprise Value per Revenue stands at 3.999 whereas that against EBITDA is 17.326.
Stock Price History:
Over the past 52 weeks, HAE has reached a high of $97.97, while it has fallen to a 52-week low of $70.25. The 50-Day Moving Average of the stock is 8.65%, while the 200-Day Moving Average is calculated to be 3.59%.
Shares Statistics:
The stock has traded on average 607.58K shares per day over the past 3-months and 932340 shares per day over the last 10 days, according to various share statistics. A total of 50.79M shares are outstanding, with a floating share count of 49.68M. Insiders hold about 1.09% of the company’s shares, while institutions hold 112.03% stake in the company. Shares short for HAE as of 1730332800 were 5161496 with a Short Ratio of 8.50, compared to 1727654400 on 5424452. Therefore, it implies a Short% of Shares Outstanding of 5161496 and a Short% of Float of 16.17.
